Five serum biomarkers for schizophrenia?

Potential metabolite markers of schizophrenia. Molecular Psychiatry. October 2011.
Download the full-text here.
View a Questioning Answers post on this paper here.

Physical health needs and schizophrenia

Physical health behaviours and health locus of control in people with schizophrenia-spectrum disorder and bipolar disorder: a cross-sectional comparative study with people with non-psychotic mental illness. BMC Psychiatry. June 2011.
Download the full-text here.

Hypothermia following antipsychotic use

An unusual case of hypothermia associated with therapeutic doses of olanzapine: a case report. Journal of Medical Case Reports. May 2011.
Download the full-text here.

Anti-malarial affects gliadin antibodies in schizophrenia

Artemisinin reduces the level of antibodies to gliadin in schizophrenia. Schizophrenia Research. May 2011.
View the abstract here.
Link to Questioning Answers post on this topic here.

Risk of diabetes in schizophrena

Diabetes prevalence estimates in schizophrenia and risk factor assessment. Annals of Clinical Psychiatry. May 2011.
View the abstract here.

Risk of schizophrenia following toxoplasma infection?

Toxoplasma infection and later development of schizophrenia in mothers. American Journal of Psychiatry. May 2011.
View the abstract here.
Link to Questioning Answers post on a similar topic here.

Using the amino acid lysine to treat schizophrenia?

L-lysine as adjunctive treatment in patients with schizophrenia: a single-blinded, randomized, cross-over pilot study. BMC Medicine. April 2011
Link to full-text here.

Biomarkers for schizophrenia?

Identification of a biological signature for schizophrenia in serum. Molecular Psychiatry. April 2011.
Link to abstract here.